Quantification of blood glial fibrillary acidic protein using a second-generation microfluidic assay. Validation and comparative analysis with two established assays.

Badrie Fazeli¹, Nerea Gómez de San José¹, Sarah Jesse¹, Makbule Senel¹, Patrick Oeckl¹,², Deborah K Erhart¹, Markus Otto³, Steffen Halbgebauer¹,²*, Hayrettin Tumani¹,²*

¹Department of Neurology, Ulm University Hospital, Ulm, Germany.
²German Center for Neurodegenerative Diseases (DZNE e.V.), Ulm, Germany.
³Department of Neurology, Halle University Hospital, Halle, Germany.

*equal contribution

Corresponding author
Prof. Hayrettin Tumani, MD, Department of Neurology, University Hospital Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany. E-mail: hayrettin.tumani@uni-ulm.de. Tel. +4973150063010. Fax: +4973150063002.

Keywords: GFAP, blood biomarker, microfluidic assay, Alzheimer’s disease, Multiple sclerosis

What is already known on this topic

- Blood glial fibrillary acidic protein (GFAP) levels are an emerging biomarker for diagnosing, prognosis and treatment monitoring for AD, MS and other neurological disorders. However, so far, the application in clinical routine remains a challenge.

What this study adds

- This study validated a novel, easy-to-use second-generation microfluidic assay for the quantitative measurement of blood GFAP. Moreover, its performance was compared to two other GFAP immunoassays, including single molecule array.

How this study might affect research, practice or policy

- This study proved the reliability, precision and reproducibility of the novel second-generation microfluidic assay, which might be more easily implemented in daily clinical routine analyses and therefore facilitates the application of GFAP as a biomarker for neurological diseases.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

**Background** Increased levels of glial fibrillary acidic protein (GFAP) in blood have been identified as a valuable biomarker for some neurological disorders, such as Alzheimer’s disease and multiple sclerosis. However, most blood GFAP quantifications so far were performed using the same bead-based assay, and to date a routine clinical application is lacking.

**Methods** In this study, we validated a novel second-generation (2nd gen) Ella assay to quantify serum GFAP. Furthermore, we compared its performance with a bead-based single molecule array (Simoa) and a homemade blood GFAP assay in a clinical cohort of neurological diseases, including 210 patients.

**Results** Validation experiments resulted in an intra-assay variation of 10%, an inter-assay of 12%, a limit of detection of 0.9 pg/mL, a lower limit of quantification of 2.8 pg/mL, and less than 20% variation in serum samples exposed to up to five freeze-thaw cycles, 120 hours at 4 °C and room temperature. Measurement of the clinical cohort using all assays revealed the same pattern of GFAP distribution in the different diagnostic groups. Moreover, we observed a strong correlation between the 2nd gen Ella and Simoa (r=0.91 (95% CI: 0.88 - 0.93), p<0.0001) and the homemade immunoassay (r=0.77 (95% CI: 0.70 - 0.82), p<0.0001).

**Conclusions** Our results demonstrate a high reliability, precision and reproducibility of the 2nd gen Ella assay. Although a higher assay sensitivity for Simoa was observed, the new microfluidic assay might have the potential to be used for GFAP analysis in daily clinical workups due to its robustness and ease of use.

**Introduction**

Human glial fibrillary acidic protein (GFAP) is a 432-amino acid long polypeptide encoded by the corresponding gene on chromosome 17q21 (1). It belongs to the type-III intermediate filaments and is responsible for maintaining the mechanical strength of astrocytes which support and regulate the blood-brain barrier (2). Moreover, GFAP is involved in fundamental and critical astrocytic functions like motility, proliferation, synaptic plasticity, myelination and responses to brain damage (3). GFAP is highly but not exclusively expressed in astrocytes in the central nervous system (4).

Reactive astrogliosis is considered to be a consequence of neurodegeneration and neuronal death and refers to morphological and functional changes in astrocytes followed by proliferation and up-regulation of GFAP (5). Because GFAP concentrations are higher in cerebrospinal fluid (CSF) than in blood, any changes in GFAP concentration are easier to detect in CSF. However, several studies demonstrated a higher discriminative power for blood compared to CSF GFAP for several diagnostic groups compared to control patients (6–8).
GFAP has recently drawn attention due to its potential as a promising biomarker for several neurological disorders where it has been shown to have value in disease diagnosis as well as disease progression and treatment monitoring (6,9). Several studies have demonstrated elevated GFAP levels in Alzheimer’s disease (AD)(8,10,11). A recent meta-analysis compared AD patients to healthy controls as well as Aβ-positive to Aβ-negative groups. The findings display a significant increase in blood GFAP levels confirming the diagnostic value of GFAP in AD (12). Furthermore, blood GFAP levels seem to increase more than 10 years before symptom onset in genetic AD patients (13,14). In addition, blood GFAP levels might be able to predict the conversion from AD mild cognitive impairment to AD dementia (10). In multiple sclerosis (MS) GFAP levels vary by MS subtype and may be used as disease severity and progression biomarker (6,15,16).

Recent advancements in highly sensitive technologies facilitated the evaluation of GFAP in several neurological conditions. However, a substantial proportion of these investigations relied upon the same single-molecule array (Simoa) platform (17–19). Therefore, these data need to be validated with an independent assay for potential use in daily clinical routine. Furthermore, efforts to enhance the ease of use of existing techniques remain essential.

In this study, we validated the performance of the novel 2nd gen commercial Ella assay for the assessment of serum GFAP. Furthermore, serum samples of a clinical cohort of 210 patients were selected to measure their GFAP levels using the 2nd gen Ella assay, the Simoa GFAP discovery kit and a sensitive homemade Ella GFAP blood assay (20). The data enabled a comparative analysis of the three assays in terms of GFAP levels in the diagnostic groups, their correlation and agreement.

**Methods**

**Patients’ samples**

In this study, 210 serum samples from seven diagnostic groups were analyzed. The samples were collected in the Department of Neurology of Ulm University Hospital between 2010 and 2021. All patients or their legal proxies were informed and signed the consent for inclusion in this study. The study was approved by the local Ethics committee from the University of Ulm (approval number: 20/10) and conducted following the Declaration of Helsinki. The clinical cohort included AD (n=44), MS (n=38), behavioral variant frontotemporal dementia (bvFTD) (n=14), Encephalitis (n=6), Meningitis (n=9), Meningoencephalitis (n=4) and control patients (Con) (n=95). AD and MS patients were diagnosed according to the International Working Group 2 criteria (21) and the 2017 revision of the McDonald criteria (22), respectively. For bvFTD diagnosis the international criteria were used (23,24). Encephalitis was diagnosed using the criteria of the International Encephalitis Consortium (25). Viral/unknown origin meningitis patients were identified by taking into account clinical symptoms of meningitis as well as CSF analysis (pleocytosis ≥ 5/µl, blood CSF barrier dysfunction, elevated lactate, possible intrathecal IgG/IgM/IgA synthesis or oligoclonal bands in CSF only). Virus
detection was performed by PCR or by testing antibodies in CSF and serum. In cases of meningitis of unknown etiology, pathogen detection was not possible.

The MS cohort consists of patients with clinically isolated syndrome (CIS n=4), relapsing-remitting MS (RRMS n=30), secondary progressive MS (SPMS n=2), and primary progressive MS (PPMS n=2). 95 Con patients were admitted to the hospital with tension-type headaches, temporary sensory symptoms and dizziness. However, neurodegenerative or neuroinflammatory conditions were ruled out after clinical and radiological evaluation. All Con patients underwent a lumbar puncture to exclude an acute or chronic inflammation of the central nervous system (CNS). This evaluation encompassed criteria such as normal leukocyte count, intact blood-CSF barrier function (i.e., normal Albumin CSF-serum ratio), and absence of intrathecal immunoglobulin synthesis (incl. quantitative analysis of IgG, IgA, IgM, and oligoclonal IgG bands).

Sample collection and analysis

To collect serum samples, venous blood was centrifuged at 2000 g for 10 min and stored within 30 min at -80°C. For stability testing, CSF was also analyzed. For this purpose, CSF samples were centrifuged at 2000 g for 10 min and aliquots were stored within 30 min at -80°C. GFAP levels were then analyzed using the 2nd gen Ella assay, Simoa assay, and a homemade Ella assay. Disease groups were randomized during measurements and two serum quality control (QC) samples were included in duplicate in all runs. To assess the repeatability of the new assay, two serum QC samples were measured in ten replicates through one run, and the intra-assay coefficient of variation (CV%) was calculated. Furthermore, the intermediate precision was determined by analyzing five replicates of two QC samples in two different runs.

The lower limit of quantification (LLOQ) and the limit of detection (LOD) were calculated based on a signal of 10 SD and 3 SD above the mean of 16 blanks, respectively. 89% of measured samples with the novel Ella assay exhibited GFAP values above the LLOQ. Parallelism was assessed in four endogenous samples (2 high and 2 low concentrations), diluted 1:2 to 1:8. Back-calculated concentrations were analyzed to determine the minimum required dilution (MRD). This approach aims to mitigate the matrix effects and ensure a reliable quantification of the endogenous GFAP. To test spike and recovery, two serum samples with low GFAP concentrations were diluted 1:2 (MRD defined in parallelism experiments) and divided into three aliquots. Subsequently, the samples were spiked with GFAP-free sample diluent, medium (100 pg/mL) and low (20 pg/mL) concentration of GFAP recombinant protein (Lyophilized Quality control, Simple Plex™). The spiked volume was less than 10% of the final aliquot volume. Recovery was calculated in percentage. To test cross-reactions to highly abundant blood proteins, serial dilutions of two serum samples were spiked with physiological blood concentrations of human albumin (40 mg/ml) and immunoglobulin G (IgG) (10 mg/ml). Subsequently, GFAP levels were compared with unspiked samples. For the homemade Ella assay, 12
samples from the cohort measurements were excluded from the analysis as GFAP values were not measurable due to errors during measurements.

**GFAP measurement**

The levels of serum GFAP in the clinical cohort were measured using the 2nd gen GFAP blood assay developed by Biocartesia on their microfluidic Ella platform (GFAP 2nd gen assay, Biocartesia, MN, USA). According to the manufacturer, the new Ella assay detects GFAP in a range of 2.52 - 9600 pg/mL. Serum samples were diluted using sample diluent SD13 (Biocartesia, MN, USA) with a dilution factor of 1:2. Additionally, serum samples were also analyzed with the same microfluidic platform, using a homemade GFAP blood assay published by Fazeli et al. (20), with slight improvements. Finally, samples were measured with the Quanterix HD-X analyzer using the Simoa GFAP Discovery kit according to the manufacturer's instructions (Quanterix, MA, USA).

**Statistics**

Data were analyzed and visualized using GraphPad Prism V.8.3.0 software (GraphPad Software, La Jolla, CA, United States). Mann-Whitney U-test and Kruskal-Wallis followed by Dunn's post-hoc tests were applied to determine the significant differences between two or more groups. The Spearman correlation coefficients were calculated between GFAP levels obtained from different assays and its relation to age. The Bland-Altman method was carried out to assess the agreement between assays. A p-value < 0.05 was considered statistically significant.

**Results**

**Performance of the 2nd gen Ella assay**

Validation experiments of the novel assay revealed an intra- and inter-assay CV of 10% and 12%, respectively. Dilution-adjusted concentrations of measured samples in the parallelism test were plotted (Fig. 1A), and a 1:2 dilution was chosen as the MRD. Considering the 1:2 dilution as an anchor, the further dilutions revealed a linear pattern. The relative error (%) of each sample was compared to the determined MRD of 1:2 with an accepted variation range of +/- 25% in the following dilutions (Fig. 1B).

*Figure 1. Parallelism assessments in four serum samples.*

The LLOQ and LOD were established at 2.8 pg/mL and 0.9 pg/mL, respectively. Stability assessments were carried out for both serum and CSF samples. The obtained data revealed that GFAP concentrations for both serum (Fig. 2A) and CSF samples (Fig. 2B) exhibited less than 20% variation when stored for up to 120 hours at either 4°C or room temperature (RT). Additionally, changes in
serum GFAP concentrations remained within an acceptable range of ±20% after undergoing five freeze-thaw cycles (FTCs) (Fig. 2C), while the CSF GFAP levels exhibited a decrease following two FTCs (Fig. 2D). The spike and recovery experiment revealed a recovery of 82% and 85% for the low and high spike concentration, respectively. No evidence of a cross-reaction with human albumin or IgG was observed.

Figure 2. Evaluation of GFAP stability in serum and CSF.

Demographic and clinical features of the diagnostic groups

Implementing the 2nd gen Ella GFAP blood, Simoa GFAP discovery, and microfluidic Ella homemade assay, 210 clinical serum samples from patients with AD (n=44), bvFTD (n=14), encephalitis (n=6), meningitis (n=9), meningoencephalitis (n=4), MS (n=38), and controls (n=95) were analyzed. According to the median, the control cohort was split into two groups: young (Y. Con, ≤50 years old) and old (O. Con, >50 years old). No significant differences existed in age between the O. Con and the AD, bvFTD, encephalitis, meningitis and meningoencephalitis group. Likewise, there was no significant age difference between the MS cohort and the Y. Con group. Table 1 provides an overview of the clinical and demographic characteristics of the diagnostic groups.

A similar pattern of positive correlation between age and GFAP concentrations, as determined with the three assays, was found in both the control and the entire cohort. The 2nd gen Ella assay showed a correlation with age of r = 0.68 (95% CI: 0.59 – 0.74), p <0.0001 for the whole cohort and r = 0.60 (95% CI: 0.44 – 0.71), p <0.0001 for the controls only. All correlations with age can be found in the supplementary materials (Fig. S1)

Cohort measurement

Comparing the GFAP assay results, the different diagnostic groups illustrated a similar GFAP concentration pattern (Fig. 3A–C). GFAP levels in AD patients were significantly higher than in the corresponding control group (O. Con) (p<0.0001 for all assays). In all three evaluations, the concentration of GFAP was considerably higher for AD patients compared to Meningitis patients (for 2nd gen Ella and Simoa p<0.0001, homemade Ella p=0.0003).

Furthermore, measurements with the homemade Ella assay displayed significantly higher levels of GFAP in AD compared to bvFTD patients (p= 0.004). However, this difference was not significant for the other two assays (2nd gen Ella p=0.05, Simoa p=0.08). In addition, the MS cohort in comparison to the associated control cohort (Y. Con), demonstrated significantly elevated GFAP levels in MS assessed by the 2nd gen Ella assay (p=0.01) and Simoa (p=0.0009) but not with the homemade Ella (p=0.4). No significant differences in GFAP level were observed between the other diagnostic groups. For sensitivity comparison purposes, the LLOQ was added to the graphs and the number of samples
below the LLOQ was calculated. For both the 2nd gen and the homemade Ella assays, the percentage of samples with a concentration below the LLOQ was 11% and 23%, respectively. All samples analyzed with the Simoa were above the LLOQ.

**Figure 3. GFAP measurement in a clinical cohort using three different GFAP assays.**

**Method correlation**

Serum GFAP levels in the whole cohort were highly correlated between the three assays (Fig. 4A-C). The strongest correlation was observed between the comparison of the novel 2nd gen Ella and the Simoa assay (r=0.91, p<0.0001). Moreover, strong correlations were also observed between the two Ella assays (r=0.77, p<0.0001) and the Simoa- homemade Ella assay (r=0.74, p<0.0001). Simple linear regression of the 2nd gen Ella and Simoa assay revealed an R² of 0.86 and a slope of 24.

**Figure 4. Pairwise correlations of serum GFAP measured by different assays.**

Bland-Altman analysis depicted prominently higher absolute values for the Simoa compared to the Ella measurements (Fig. 5 & S 2A,B). Most of the observations were within the limit of agreement, as assessed by the confidence lines. Furthermore, the analysis revealed greater variability between assays in the lower detection range compared to the relatively more consistent results observed at higher GFAP levels.

**Figure 5. Bland-Altman analysis.**

**Conclusion**

In this study, we thoroughly validated the novel 2nd gen GFAP Ella assay for its use in serum analysis. Additionally, we compared the results of a clinical cohort measurement with two existing blood GFAP assays and correlated the assays among each other. Validation experiments demonstrated a good precision for the 2nd gen Ella assay, as both intra- and inter-assay CVs were clearly in an acceptable range below 15% (26). Moreover, the recovery rate of spiked GFAP protein was above 80%, suggesting a low interference of serum matrix effects.

The LLOQ and LOD of the 2nd gen Ella assay were calculated to be 2.8 and 0.9 pg/mL, respectively. These values were higher than the Quanterix Simoa GFAP discovery kit (LLOQ: 1.3 pg/mL, LOD:0.2 pg/mL) and lower than the homemade Ella assay (LLOQ: 3.8 pg/mL, LOD 1.6 pg/mL, Fazeli et al., 2023, modified). In addition, all analyzed samples were above the LLOQ for the Simoa analysis (11% and 23% below the LLOQ for the 2nd gen and homemade assay, respectively) demonstrating that while
the 2nd gen Ella GFAP offers greater sensitivity than the homemade assay its assay sensitivity is
inferior to the Simoa. This might be due to the highly sensitive digital bead-based system used for
Simoa analyses.

Furthermore, we also detected a huge difference between absolute GFAP concentrations, with
markedly higher levels detected by the Simoa assay. This difference was further illustrated by the
Bland-Altman plot, showing on average more than 20 times higher GFAP levels for Simoa. While we
can only hypothesize the reason behind this, it is plausible that the discrepancy arises from the
different antibodies used in each assay, potentially binding to different epitopes. Consequently, this
could lead to the measurement of different GFAP isoforms or breakdown products, which could be
present in the blood at different concentrations. A more straightforward explanation could be different
calibrations of the standard curve. The latter might be more likely as we demonstrate a very strong
correlation between the 2nd gen Ella and Simoa, hinting at the measurement of the same GFAP proteins
in the assays. Nonetheless, it is important to mention that the 2nd gen Ella and the Simoa assays
cannot be used interchangeably.

The stability tests displayed stable serum GFAP concentrations after storage at either room
temperature or 4°C for up to 120 hours and up to five freeze-thaw cycles. This robust stability
facilitates sample handling in daily clinic use. As CSF GFAP concentrations are reported to decline
after several FTCs using the Simoa and homemade GFAP assays (20,27), we decided to also include
CSF in the stability tests of the 2nd gen GFAP Ella assay. CSF GFAP levels could sustain storage at
4°C and room temperature for up to 120 hours, but after two freeze-thaw cycles, they also began to
decline using the 2nd gen Ella assay. Therefore, we recommend using only fresh CSF samples for
GFAP analysis when applying the 2nd gen Ella assay.

Taken together, validation assessments demonstrated a good performance of the 2nd gen Ella assay. For
that reason, we proceeded to employ the assay for the analysis of a clinical cohort of 210 patients.
Subsequently, we compared the results to two alternative GFAP assays. The obtained results revealed
the same GFAP concentration pattern independent of the assay applied, suggesting the analysis of the
same GFAP isoform or breakdown product. This is further strengthened by the strong correlation
between the assays, especially the 2nd gen and Simoa GFAP assay. The ratio Bland-Altman plot also
demonstrated a good agreement among the assays. However, at lower GFAP concentrations, the assays
exhibited increased variability, potentially due to the lower assays sensitivity in that concentration
range.

Additionally, we assessed the correlation between GFAP levels and age within the control and the
whole cohort, using the three assays. A strong and positive correlation was apparent in the results
obtained from the 2nd gen Ella and the Simoa assays when assessing both the control group and whole
cohort which confirms previous studies (10,28).
When evaluating the differences in GFAP levels among the diagnostic groups, we also observed a prominent GFAP increase among individuals with AD compared to control patients, as evidenced by all three assays. These results align with previous research findings (7,8,10). For the comparison AD and bvFTD, literature reports a significant elevation in AD. In our study, we did only observe a clear trend to increased levels in AD but did not find a significant difference using the 2nd gen Ella or Simoa. This is most likely due to the low number of bvFTD patients measured, and further studies using 2nd gen Ella to investigate more samples need to be performed.

Comparison of GFAP levels between the MS cohort and the young controls demonstrated a significant increase in MS patient values measured by the 2nd gen Ella and the Simoa assays, as has been shown in previous studies (29–32). However, no significant elevation was observed using the homemade Ella. A possible explanation may be the lower sensitivity of the homemade assay compared to the other two assays, leading to a higher overlap between MS and control patients. The observed trend to elevated levels in encephalitis patients proof the literature that GFAP is not a specific disease marker and inflammation of the brain parenchyma can already lead to increased blood GFAP levels (33).

The study's limitations are primarily attributed to the small number of patients in some diagnostic groups, which restricts the ability to draw precise and definitive conclusions concerning their GFAP levels using the 2nd gen Ella assay. This also limited the possibility of analyzing the different MS subgroups within the MS category. Despite these limitations, our study presents several notable strengths. First, we conducted a comprehensive validation of the novel microfluidic highly sensitive assay and confirmed its reproducibility, robustness, and reliability. Second, we measured GFAP levels in a well-characterized clinical cohort, including various neurological diseases. Third, we correlated the GFAP levels with two already established assays rendering it possible to compare the results with current GFAP literature.

In conclusion, our findings show the robustness and reliability of the novel 2nd gen Ella assay for the quantification of serum GFAP. The assay displays a strong correlation with the currently most used GFAP blood immunoassays with the limitation of a lower sensitivity compared to bead-based approaches. Still the assay could be a cost-effective alternative for GFAP analysis and, due to its ease of use, has a strong potential to be applied in routine clinical GFAP measurements.

**Acknowledgments**

We would like to thank all participating patients and the Bio-Techne Ella development team for providing the 2nd gen Ella cartridges. Bio-Techne was not involved in any analysis or interpretation of data.

**Competing interests**

NGdSJ is a part-time employer at Proteintech. All other authors declare no competing interests.
Funding

This study was supported by the EU Joint Programme-Neurodegenerative Diseases networks Genfi-Prox (01ED2008A), the German Federal Ministry of Education and Research (FTLDc 01GI1007A), the EU Moodmarker programme (01EW2008), the German Research Foundation/DFG (SFB1279), the foundation of the state Baden-Wuerttemberg (D.3830), Boehringer Ingelheim Ulm University BioCenter (D.5009).

Author contributions

Conception and design of the study: BF, SH, HT; sample collection and data management: BF, NGdSJ, PO, SJ, MS, DE, MO, SH, HT; study management and coordination: BF, SH, HT; statistical methods and analysis: BF, SH, HT; interpretation of results: BF, NGdSJ, PO, SJ, MS, DE, MO, SH, HT; manuscript writing (first draft): BF, SH, HT; All authors critically revised the manuscript and approved the final version.

Tables

Table 1. Demographic and clinical parameters of the diagnostic groups.

<table>
<thead>
<tr>
<th></th>
<th>O. Con</th>
<th>AD</th>
<th>bvFTD</th>
<th>Enc</th>
<th>Men</th>
<th>ME</th>
<th>MS</th>
<th>Y. Con</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>48</td>
<td>44</td>
<td>14</td>
<td>6</td>
<td>9</td>
<td>4</td>
<td>38</td>
<td>47</td>
</tr>
<tr>
<td>No. Female (%)</td>
<td>24(50)</td>
<td>28 (63)</td>
<td>6 (43)</td>
<td>2 (33)</td>
<td>3 (33)</td>
<td>2 (50)</td>
<td>21 (55)</td>
<td>26(55)</td>
</tr>
<tr>
<td>Age (year)</td>
<td>61 (54-70)</td>
<td>68 (64-75)</td>
<td>64 (59-73)</td>
<td>77 (59-79)</td>
<td>70 (54-80)</td>
<td>64 (51-79)</td>
<td>64 (51-79)</td>
<td>32 (28-43)</td>
</tr>
<tr>
<td>2nd gen Ella Serum GFAP (pg/mL)</td>
<td>6.78 (5.21-9.36)</td>
<td>14.35 (10.98-19.41)</td>
<td>7.85 (5.62-12.11)</td>
<td>12.56 (8.04-13.85)</td>
<td>4.38 (2.92-5.77)</td>
<td>6.17 (2.08-12.57)</td>
<td>4.71 (3.24-7.46)</td>
<td>4.12 (2.80-5.08)</td>
</tr>
<tr>
<td>Simoa Serum GFAP (pg/mL)</td>
<td>155.1 (119.2-215.6)</td>
<td>361 (249.2-496.3)</td>
<td>225.2 (152.2-277.5)</td>
<td>268.1 (169-333.9)</td>
<td>122.7 (81.13-155.5)</td>
<td>105.3 (54.75-226)</td>
<td>115.2 (81.13-155.5)</td>
<td>110.9 (57.80-111.9)</td>
</tr>
<tr>
<td>Homemade Ella Serum GFAP (pg/mL)</td>
<td>5.52 (4.04-8.11)</td>
<td>10.88 (8.38-13.04)</td>
<td>6.01 (3.48-8.55)</td>
<td>8.50 (5.52-13.42)</td>
<td>4.56 (3.91-5.64)</td>
<td>12.17 (4.09-13.22)</td>
<td>4.47 (3.49-6.01)</td>
<td>4.12 (2.70-5.51)</td>
</tr>
</tbody>
</table>

Age and concentrations are given as median with interquartile range in brackets. AD, Alzheimer's disease; bvFTD, behavioral variant frontotemporal dementia; Enc, Encephalitis; GFAP, Glial fibrillary acidic protein; Men, Meningitis; ME, Meningoencephalitis; MS, multiple sclerosis; O. Con, Old control; Simoa, Single-molecule array; Y. Con, Young control.

Figure titles and legends

Figure 1. Parallelism assessments in four serum samples.

(A) Back-calculated GFAP concentrations of four samples with low-, medium- and high GFAP concentrations. (B) Using 1:2 dilution as the MRD, the relative error in subsequent dilutions was within the accepted limitations of 75-125%. Sample 1 had a very low GFAP concentration and a dilution of 1:8 resulted in a near blank-level signal; therefore, a variation above 25% was observed. GFAP, glial fibrillary acidic protein; MRD, minimum required dilution.

Figure 2. Evaluation of GFAP stability in serum and CSF.
The stability of GFAP in serum and CSF was determined by comparing the relative content of GFAP in two serum samples (A) and two CSF samples (B) after storage at room temperature or 4°C, in comparison to the reference samples. Variations were found to be less than ±20%. Multiple freeze-thaw cycles were performed, and two serum (C) and CSF samples (D) were compared to the reference samples to assess GFAP's relative concentration. Serum GFAP remained stable after undergoing up to five FTCs, while GFAP levels in CSF decreased after two cycles. CSF, cerebrospinal fluid, FTC, freeze-thaw cycle, GFAP, glial fibrillary acidic protein.

Figure 3. GFAP measurement in a clinical cohort using three different GFAP assays.
(A) 2nd gen Ella assay (n=210), (B) Simoa discovery kit (n=210), (C) homemade Ella assay (n=198). GFAP levels in the diagnostic groups were compared to the corresponding control cohort (Con) in the same age range. Boxes represent the median and interquartile range, with whiskers for minimum and maximum. The red-dotted lines represent the lower limit of quantification of each assay. The Mann-Whitney U-test was employed to compare GFAP levels between MS patients and young control patients. For the remaining comparisons, the Kruskal-Wallis test was initially conducted, followed by Dunn’s post-hoc test AD, Alzheimer’s disease; bvFTD, behavioral variant frontotemporal dementia; Enc, Encephalitis; GFAP, Glial fibrillary acidic protein; Men, Meningitis; ME, Meningoencephalitis; MS, multiple sclerosis; O. Con, Old control; Simoa, Single-molecule array; Y. Con, Young control.

Figure 4. Pairwise correlations of serum GFAP measured by different assays.
(A) Correlation between the novel 2nd gen Ella assay and the Simoa assay in 210 samples with a correlation coefficient of r=0.91 (95% CI: 0.88 - 0.93, p<0.0001).(B) Correlation between the 2nd gen Ella assay and the homemade Ella assay in 198 samples, with a correlation coefficient of r=0.77 (95% CI: 0.70 - 0.82, p<0.0001).(C) Correlation between the Simoa and the homemade Ella assay in 198 samples with a correlation coefficient of r=0.74 (95% CI: 0.67 - 0.80, p<0.0001). CI, Confidence interval; GFAP, Glial fibrillary acidic protein; Simoa, Single-molecule array.

Figure 5. Bland-Altman analysis.
Bland-Altman plot evaluates the agreement between the novel Ella and the Simoa assay. Circles illustrate the ratio of Simoa to 2nd gen Ella GFAP for each sample (N = 210; Mean = 24.7 ; lower limit of agreement = 10.25; upper limit of agreement = 39.19 ). The 95% limits of agreement were displayed with horizontal red dotted lines in the graph, defined as the mean ratio of Simoa to 2nd gen Ella GFAP values ±1.96 times the SD of the ratios. The solid green line represents the mean ratio. 2nd gen Ella, second generation Ella; GFAP, Glial fibrillary acidic protein; SD, standard deviation; Simoa, Single-molecule array.

References


A

\[ \rho = 0.91^{****} \]

B

\[ \rho = 0.77^{****} \]

C

\[ \rho = 0.74^{****} \]